Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
Syndax Pharmaceuticals (SNDX) has scheduled its fourth quarter and full year 2024 financial results announcement and business update for Monday, March 3, 2025. The company will host a conference call and live audio webcast at 8:00 a.m. ET on the same day.
Investors and interested parties can access the webcast through the Events & Presentations page in the Investors section of Syndax's website. Alternative access is available via phone using the conference ID: Syndax4Q24, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800.
A replay of the conference call will be available on the company's website approximately 24 hours after the event and will remain accessible for 90 days.
Syndax Pharmaceuticals (SNDX) ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno 2024 per lunedì 3 marzo 2025. L'azienda ospiterà una conferenza telefonica e una trasmissione audio in diretta alle 8:00 a.m. ET dello stesso giorno.
Gli investitori e le parti interessate possono accedere alla trasmissione attraverso la pagina Eventi e Presentazioni nella sezione Investitori del sito web di Syndax. È disponibile un accesso alternativo tramite telefono utilizzando l'ID conferenza: Syndax4Q24, con numero di accesso nazionale 800-590-8290 e numero di accesso internazionale 240-690-8800.
Una registrazione della conferenza sarà disponibile sul sito web dell'azienda circa 24 ore dopo l'evento e rimarrà accessibile per 90 giorni.
Syndax Pharmaceuticals (SNDX) ha programado el anuncio de resultados financieros del cuarto trimestre y del año completo 2024 para el lunes 3 de marzo de 2025. La compañía llevará a cabo una llamada de conferencia y una transmisión de audio en vivo a las 8:00 a.m. ET el mismo día.
Los inversores y partes interesadas pueden acceder a la transmisión a través de la página de Eventos y Presentaciones en la sección de Inversores del sitio web de Syndax. También hay acceso alternativo por teléfono utilizando el ID de conferencia: Syndax4Q24, con número de acceso nacional 800-590-8290 y número de acceso internacional 240-690-8800.
Una repetición de la llamada de conferencia estará disponible en el sitio web de la compañía aproximadamente 24 horas después del evento y seguirá accesible durante 90 días.
Syndax Pharmaceuticals (SNDX)는 2025년 3월 3일 월요일에 2024년 4분기 및 연간 재무 결과 발표와 비즈니스 업데이트를 예정하고 있습니다. 회사는 같은 날 오전 8시 ET에 컨퍼런스 콜 및 라이브 오디오 웹캐스트를 진행합니다.
투자자 및 관심 있는 당사자는 Syndax 웹사이트의 투자자 섹션에 있는 이벤트 및 프레젠테이션 페이지를 통해 웹캐스트에 접근할 수 있습니다. 전화로도 접근이 가능하며, 컨퍼런스 ID는 Syndax4Q24입니다. 국내 전화번호는 800-590-8290, 국제 전화번호는 240-690-8800입니다.
컨퍼런스 콜의 녹음은 이벤트 후 약 24시간 이내에 회사 웹사이트에서 제공되며, 90일 동안 접근할 수 있습니다.
Syndax Pharmaceuticals (SNDX) a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le lundi 3 mars 2025. L'entreprise organisera une conférence téléphonique et un webinaire audio en direct à 8h00 ET le même jour.
Les investisseurs et les parties intéressées peuvent accéder au webinaire via la page Événements et Présentations dans la section Investisseurs du site web de Syndax. Un accès alternatif est disponible par téléphone en utilisant l'ID de conférence : Syndax4Q24, avec le numéro d'appel national 800-590-8290 et le numéro d'appel international 240-690-8800.
Un enregistrement de la conférence sera disponible sur le site web de l'entreprise environ 24 heures après l'événement et restera accessible pendant 90 jours.
Syndax Pharmaceuticals (SNDX) hat die Bekanntgabe der finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 für Montag, den 3. März 2025 angesetzt. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und eine Live-Audio-Webcast veranstalten.
Investoren und interessierte Parteien können über die Seite Veranstaltungen & Präsentationen im Investorenbereich der Syndax-Website auf den Webcast zugreifen. Alternativ ist der Zugang auch telefonisch möglich, unter Verwendung der Konferenz-ID: Syndax4Q24, mit der nationalen Einwahlnummer 800-590-8290 und der internationalen Einwahlnummer 240-690-8800.
Eine Wiederholung der Telefonkonferenz wird etwa 24 Stunden nach der Veranstaltung auf der Website des Unternehmens verfügbar sein und bleibt 90 Tage lang zugänglich.
- None.
- None.
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its fourth quarter and full year 2024 financial results and provide a business update on Monday, March 3, 2025.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 8:00 a.m. ET on Monday, March 3, 2025 to discuss the Company's financial results and provide a business update.
The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax4Q24
Domestic Dial-in Number: 800-590-8290
International Dial-in Number: 240-690-8800
Live webcast: https://www.veracast.com/webcasts/syndax/events/SNDX4Q24.cfm
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website at www.syndax.com approximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
FAQ
When will Syndax (SNDX) release Q4 and full year 2024 earnings?
What time is the SNDX Q4 2024 earnings call?
How can investors access SNDX's Q4 2024 earnings call?
How long will SNDX's Q4 2024 earnings call replay be available?
